![Konji Sebati](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Konji Sebati
Algemeen Directeur bij Innovative Pharmaceutical Association South Africa
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
David Reddy | M | - |
MMV Medicines for Malaria Venture
![]() MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | 14 jaar |
Alan Court | M | - |
Ivcc
![]() Ivcc Miscellaneous Commercial ServicesCommercial Services IVCC is a British company that works to prevent vector-borne diseases and combat insecticide resistance. The private company is based in Liverpool, UK. The company achieves this by directly targeting the vector that transmits the disease. The company's Research & Development Portfolio is dedicated to innovative work that prevents vector-borne diseases and tackles insecticide resistance. IVCC was founded in 2005, and the CEO is Nick Hamon.
MMV Medicines for Malaria Venture
![]() MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | - |
Per Wold-Olsen | M | 76 |
MMV Medicines for Malaria Venture
![]() MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | - |
Jeremy Lefroy | M | - |
Ivcc
![]() Ivcc Miscellaneous Commercial ServicesCommercial Services IVCC is a British company that works to prevent vector-borne diseases and combat insecticide resistance. The private company is based in Liverpool, UK. The company achieves this by directly targeting the vector that transmits the disease. The company's Research & Development Portfolio is dedicated to innovative work that prevents vector-borne diseases and tackles insecticide resistance. IVCC was founded in 2005, and the CEO is Nick Hamon. | - |
Wendy R. Sanhai | M | - |
MMV Medicines for Malaria Venture
![]() MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | - |
Joy Phumaphi | F | - |
MMV Medicines for Malaria Venture
![]() MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | - |
Robert Newman | M | - |
MMV Medicines for Malaria Venture
![]() MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | - |
Yuli Ismartono | F | - |
MMV Medicines for Malaria Venture
![]() MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | - |
Winston E. Gutteridge | M | - |
MMV Medicines for Malaria Venture
![]() MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | 15 jaar |
Michael Ferguson | M | - |
MMV Medicines for Malaria Venture
![]() MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | - |
David Brandling-Bennett | M | - |
MMV Medicines for Malaria Venture
![]() MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | - |
Nick Hamon | M | - |
Ivcc
![]() Ivcc Miscellaneous Commercial ServicesCommercial Services IVCC is a British company that works to prevent vector-borne diseases and combat insecticide resistance. The private company is based in Liverpool, UK. The company achieves this by directly targeting the vector that transmits the disease. The company's Research & Development Portfolio is dedicated to innovative work that prevents vector-borne diseases and tackles insecticide resistance. IVCC was founded in 2005, and the CEO is Nick Hamon. | - |
Qiyong Liu | M | - |
Ivcc
![]() Ivcc Miscellaneous Commercial ServicesCommercial Services IVCC is a British company that works to prevent vector-borne diseases and combat insecticide resistance. The private company is based in Liverpool, UK. The company achieves this by directly targeting the vector that transmits the disease. The company's Research & Development Portfolio is dedicated to innovative work that prevents vector-borne diseases and tackles insecticide resistance. IVCC was founded in 2005, and the CEO is Nick Hamon. | - |
Jonathan Schofield | M | 63 |
Ivcc
![]() Ivcc Miscellaneous Commercial ServicesCommercial Services IVCC is a British company that works to prevent vector-borne diseases and combat insecticide resistance. The private company is based in Liverpool, UK. The company achieves this by directly targeting the vector that transmits the disease. The company's Research & Development Portfolio is dedicated to innovative work that prevents vector-borne diseases and tackles insecticide resistance. IVCC was founded in 2005, and the CEO is Nick Hamon. | - |
Elizabeth Chizema-Kawesha | M | - |
Ivcc
![]() Ivcc Miscellaneous Commercial ServicesCommercial Services IVCC is a British company that works to prevent vector-borne diseases and combat insecticide resistance. The private company is based in Liverpool, UK. The company achieves this by directly targeting the vector that transmits the disease. The company's Research & Development Portfolio is dedicated to innovative work that prevents vector-borne diseases and tackles insecticide resistance. IVCC was founded in 2005, and the CEO is Nick Hamon. | - |
Sherwin Charles | M | - |
Ivcc
![]() Ivcc Miscellaneous Commercial ServicesCommercial Services IVCC is a British company that works to prevent vector-borne diseases and combat insecticide resistance. The private company is based in Liverpool, UK. The company achieves this by directly targeting the vector that transmits the disease. The company's Research & Development Portfolio is dedicated to innovative work that prevents vector-borne diseases and tackles insecticide resistance. IVCC was founded in 2005, and the CEO is Nick Hamon. | - |
Elizabeth J. Linder | F | - |
MMV Medicines for Malaria Venture
![]() MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | - |
Dennis Schmatz | M | - |
MMV Medicines for Malaria Venture
![]() MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | - |
Stephen O'Brien | M | 67 |
Ivcc
![]() Ivcc Miscellaneous Commercial ServicesCommercial Services IVCC is a British company that works to prevent vector-borne diseases and combat insecticide resistance. The private company is based in Liverpool, UK. The company achieves this by directly targeting the vector that transmits the disease. The company's Research & Development Portfolio is dedicated to innovative work that prevents vector-borne diseases and tackles insecticide resistance. IVCC was founded in 2005, and the CEO is Nick Hamon. | - |
Dominique Limet | M | - |
MMV Medicines for Malaria Venture
![]() MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | - |
Pascal Housset | M | - |
Ivcc
![]() Ivcc Miscellaneous Commercial ServicesCommercial Services IVCC is a British company that works to prevent vector-borne diseases and combat insecticide resistance. The private company is based in Liverpool, UK. The company achieves this by directly targeting the vector that transmits the disease. The company's Research & Development Portfolio is dedicated to innovative work that prevents vector-borne diseases and tackles insecticide resistance. IVCC was founded in 2005, and the CEO is Nick Hamon. | - |
Andrea Buscaglia | M | 60 |
MMV Medicines for Malaria Venture
![]() MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | - |
Gabriel Jaramillo-Sanint | M | 74 |
MMV Medicines for Malaria Venture
![]() MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | - |
Andrea Lucard | F | - |
MMV Medicines for Malaria Venture
![]() MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Leapeetswe Rapula Radiala Molotsane | M | - | - | |
Lulamile Xate | M | - | 7 jaar | |
Michael Charles Meintjes | M | - | 6 jaar | |
Sechaba Selibe | F | - | - | |
Paul John Jury | M | 66 | 7 jaar | |
Brendan O'Regan | M | - | - | |
Denis Joseph Gately | M | - | 2 jaar | |
Robert Croll | M | - | 7 jaar | |
Michael Gray | M | - | 4 jaar | |
Colin Gilligan | M | - | 7 jaar | |
Johnny Prinsloo | M | - | 4 jaar | |
Robert David Norman Lowe | M | - | 3 jaar | |
Manish Dahiya | M | 46 | - | |
Zirk van der Bank | M | - | 5 jaar | |
Peter Watson | M | 62 | 1 jaar | |
Brian David Warner | M | - | 5 jaar | |
Eryl Baron | F | - | - | |
Geoffrey Rose | M | 88 | - | |
Gregory Hunter | M | 58 | 2 jaar | |
Brian Harvey | M | - | 1 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Zuid-Afrika | 20 | 45.45% |
Zwitserland | 16 | 36.36% |
Verenigd Koninkrijk | 9 | 20.45% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Konji Sebati
- Persoonlijk netwerk